254 - Optimizing Stewardship Interventions in Challenging Populations

Saturday, October 22, 2022

1:45 PM – 3:00 PM US ET

Location: 201

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Pranita Tamma, MD, MHS

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland, United States

Disclosure(s): No financial relationships to disclose
Erin McCreary, PharmD

Clinical Assistant Professor, Director of Infectious Diseases Improvement and Clinical Research Innovation
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States

Disclosure(s): AbbVie Inc: Advisor/Consultant (Ongoing); Cidara Therapeutics Inc.: Advisor/Consultant (Ongoing); Entasis Pharmaceuticals: Advisor/Consultant (Ongoing); Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant (Ongoing); La Jolla Pharmaceuticals: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing); Summit pharmaceuticals: Advisor/Consultant (Ongoing)

Faculty(s)

Kathleen Chiotos, MD, MSCE

Assistant Professor
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States

Disclosure(s): No financial relationships to disclose

Slides
Michael Pulia, MD PhD

Assistant Professor
Emergency Medicine
University of Wisconsin-Madison
Madison, Wisconsin, United States

Disclosure(s): No financial relationships to disclose

Slides
Dilek Ince, MD

Clinical Professor of Internal Medicine-Infectious Diseases
Internal Medicine, Infectious Diseases
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States

Disclosure(s): Moderna, Inc.: Site PI for clinical study- study funds for institution (Ongoing)

Slides

Disclosure(s):

Pranita Tamma, MD, MHS: No financial relationships to disclose

Erin K. McCreary, PharmD: AbbVie Inc: Advisor/Consultant (Ongoing); Cidara Therapeutics Inc.: Advisor/Consultant (Ongoing); Entasis Pharmaceuticals: Advisor/Consultant (Ongoing); Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant (Ongoing); La Jolla Pharmaceuticals: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing); Summit pharmaceuticals: Advisor/Consultant (Ongoing)

Kathleen Chiotos, MD, MSCE: No financial relationships to disclose

Michael Pulia, MD PhD: No financial relationships to disclose

Dilek Ince, MD: Moderna, Inc.: Site PI for clinical study- study funds for institution (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify novel stewardship interventions to develop and implement in the ICU setting;
describe novel stewardship interventions to develop and implement in the emergency department;
explain novel stewardship interventions to develop and implement in the transplant infectious diseases population

Presentations:

1:45 PM – 2:10 PM US ET

Novel Approaches to Stewardship in the ICU Setting
Speaker: Kathleen Chiotos, MD, MSCE – Children's Hospital of Philadelphia
2:10 PM – 2:35 PM US ET

Novel Approaches to Stewardship in the Emergency Department
Speaker: Michael Pulia, MD PhD – University of Wisconsin-Madison
2:35 PM – 3:00 PM US ET

Novel Approaches to Stewardship in the Transplant Infectious Diseases Population
Speaker: Dilek Ince, MD – University of Iowa Hospitals & Clinics